Contineum Therapeutics reports positive Phase 1b data for PIPE-791

5 articles · Updated · MarketWatch · Apr 30

The exploratory trial showed pain reductions in chronic osteoarthritis pain, with shares rising 7.6% after hours to $13.80 after closing up 6.5% at $12.82.
Contineum said PIPE-791, a selective lysophosphatidic acid 1 receptor antagonist, showed improvement trends across average daily pain, worst daily pain and patients achieving at least 30% pain reduction.
Chief medical officer Timothy Watkins said the treatment was well tolerated and the findings support considering further clinical development; the stock was up 12% year to date at the close.

After a rival's drug failed, has this company found the key to a safer, non-addictive painkiller?

This new drug targets pain, anxiety, and tissue scarring. Could its broad effects hide unforeseen risks?